Why May 2026 is a very interesting window to sell a multi-vet practice in Australia.

Markets are mostly boring. Then occasionally they’re not.

Markets are mostly boring. They have long, uneventful periods punctuated by short windows when something unusual happens. I don’t love using the word window, because it has been overused by people trying to sell you things. But this is a window in the literal sense: open for now, definitely closing eventually, the air still moving through it.

May 2026 is one of those windows in Australian veterinary consolidation. It’s not permanent. It won’t stay open at this intensity. Which is the part most owners don’t quite believe until later, when they’re looking back at it. But right now, for owners of multi-vet practices producing $1M+ in normalised EBITDA, the configuration of buyers in this market is unusually strong.

Here’s why.

The buyers, briefly.

VetPartners is owned by EQT, the Swedish private equity firm, which acquired it in late 2023 for around $1.4B. About 267 clinics across Australia and New Zealand. EQT is 15 months into a typical 4–7 year hold cycle. Still in buying mode.

Greencross is majority-owned by TPG, with AustralianSuper and HOOPP. Industry research has referenced a potential ASX relisting. Whether or not that proceeds, the platform is still acquiring.

CVS Group, the UK-listed consolidator, entered Australia in mid-2024 and reached 51 sites by September 2025. Still in entry-and-scale mode, historically the phase where foreign entrants pay competitive prices to establish density.

Apiam Animal Health is ASX-listed with a regional and rural focus. A different rhythm. Public-market accountability. Active, but not on every metropolitan opportunity.

Plus Vets Central (Pemba Capital Partners, 45+ clinics), specialty roll-ups, opportunistic strategics. The bid table for a well-prepared multi-vet practice is unusually crowded for a market this size.

This is what a window looks like. Three or four credible bidders simultaneously in active acquisition mode. It’s rare. It doesn’t last.

Why the window will close.

Three things will compress this environment over 18–36 months.

If Greencross relists, post-IPO acquisition discipline tends to harden. Public-market buyers have to defend every multiple to analysts who are paid to be sceptical.

CVS will eventually move from land-grab to optimization. When that happens, bidding becomes selective. Foreign entrants don’t pay competitive entry prices forever.

EQT will progress through the VetPartners hold cycle toward preparing for exit. Platforms shift from buying to running.

None of this is happening this month. All of it is a recognisable pattern approaching on the horizon if you raise your binoculars to the right angle.

Where multiples sit.

For multi-vet practices transacting in May 2026, sub-$20M deals are trading, illustratively, in three bands on Adjusted EBITDA. Roughly 7x to 9x at the top tier. 5x to 6.5x in the middle. 3.5x to 5x at the lower tier.

The spread between top and bottom is the widest it’s been in a decade.

Here’s what’s worth noting: it isn’t driven by location alone. Two practices a kilometre apart, both producing $1.2M EBITDA, can trade at $7M and $4.5M.

The difference is preparation.

What buyers are actually buying.

Consolidators in 2026 are buying durable cash flows, retention of clinical staff, and a client base that doesn’t depend on the seller’s relationships. That last one matters more than most owners expect.

Three things driving valuation at an outsized rate in current diligence:

Vet retention post-close. A practice with two associates on three-to-five-year agreements is worth materially more than the same practice with at-will associates and a selling lead vet. Mass walkout risk is modelled and priced.

Recurring revenue and retention metrics. Wellness plans, repeat consultation rates, lifetime value. Practices that can produce a clean retention chart get a different conversation than practices showing only top-line revenue.

EBITDA durability and add-back defensibility. Add-backs that don’t hold up reduce both the headline number and the trust behind it.

What to do, if you’re considering selling.

Five operational areas matter most.

Lease term. Under three years remaining is a negotiating weakness. If you own the premises, decide early whether to sell with the business, retain and lease back, or sell separately. Each has different tax and valuation implications.

Staff agreements. Every clinical staff member on a current, enforceable agreement. Key associates on retention bonuses.

Financial cleanup. Three years of clean, normalised financials. A quality of earnings review from your accountant in advance.

Practice management software. Modern PMS with clean data, traceable revenue, and extractable retention metrics. Legacy software is a discount.

Compliance and clinical governance. Drug schedule, radiation licensing, employment law, WHS. None of this creates upside. Each gap creates downside.

What the next 18 months may actually look like

The atmosphere should remain positive in the short to medium term. That doesn’t mean rushing.

The practices trading at the top of their range this year are the ones that came to market prepared. Clean financials, locked-in teams, secure premises, modern systems, and a credible story about cash flow without the founder.

The decision to sell is yours. The decision about whether your practice is ready when you make that decision largely drives the number on the page.